Given that NFκB activation may contribute to metabolic disease and aging in part through dysregulation of BMAL1 circadian systems, further study can take NFκB into consideration as a plausible target for therapeutic repression in anti-aging. This evidence concerns the gene NFKB1 and Other metabolic disease.